SAB Biotherapeutics EBITDA

What does SAB Biotherapeutics do? SAB Biotherapeutics, Inc. generates revenue by developing immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. The company utilizes its DiversitAb platform to produce fully human polyclonal immunotherapies without the need for human donors. This approach targets serious unmet needs in human diseases through its clinical-stage pipeline. The company markets specific product candidates including SAB-185, a fully human polyclonal antibody therapeutic for the treatment of coronavirus disease, and SAB-176, a multivalent, neutralizing fully human polyclonal antibody therapeutic candidate designed to bind to Type A and B influenza viruses. These products are directed at patients and healthcare providers seeking treatments for viral infections. Additionally, the company develops preclinical stage assets such as SAB-195, the first-in-class fully human hIgG treatment for the treatment of Clostridioides difficile infection, and SAB-142, a multi-indication potential asset developed for organ transplant induction and organ transplant rejection. These assets aim to address immunological indications and severe bacterial infections within the biopharmaceutical market. SAB Biotherapeutics is one of the most popular companies on Eulerpool.